This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Infections can occur anywhere from December to June, and can take place throughout any point during and following harvesting. Transmission can occur mechanically, or via conidial dispersal in water or air to fruit surfaces. Conidia often reside within soil, but can also be found in the air of contaminated storage spaces. Being a wound pathogen, fruit injuries are required for successful fruit infections, with much of these injuries occurring due to improper handling during the harvesting process. Injuries can also be caused by other events such as frost and insect bites, and can be as minor as damage to fruit skin oil glands. Fallen fruit can also be susceptible to P. digitatum infections, as has been noted in Israel, where P. digitatum infects fallen fruit more than P. italicum. Pathogenicity of P. digitatum is suggested to rely on the acidification of the infected fruit. During fruit decay, this species has been observed to make citric acid and gluconic acid and sequester ammonium ions into its cytoplasm. The low pH may aid in the regulation of various gene-encoded pathogenic factors such as polygalactouronases. In addition, P. digitatum has been observed to modify plant defense mechanisms, including phenylalanine ammonia lyase activity, in the citrus fruits it infects. Modifications to the disease cycle of P. digitatum have been induced experimentally. For example, P. digitatum has been observed to cause infection in unwounded fruits through mechanical transmission, although a higher infection dose was required in such instances.
The white paper that led to the Local Government Act 1972 proposed as "area 2" a metropolitan county including Newcastle and Sunderland, extending as far south down the coast as Seaham and Easington, and bordering "area 4" (which would become Tees Valley). The Bill as presented in November 1971 pruned back the southern edge of the area, and gave it the name "Tyneside". The name "Tyneside" proved controversial on Wearside, and a government amendment changed the name to "Tyne and Wear" at the request of Sunderland County Borough Council.
=== Selected articles === Townsend, D. M., Tew, K. D., & Tapiero, H. (2003). The importance of glutathione in human disease. Biomedicine & pharmacotherapy, 57(3-4), 145–155. Townsend, D. M., & Tew, K. D. (2003). The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene, 22(47), 7369–7375. Townsend, D. M., Deng, M., Zhang, L., Lapus, M. G., & Hanigan, M. H. (2003). Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. Journal of the American Society of Nephrology: JASN, 14(1), 1. Tapiero, H., Townsend, D. M., & Tew, K. D. (2004). The role of carotenoids in the prevention of human pathologies. Biomedicine & Pharmacotherapy, 58(2), 100–110. Grek, C. L., Zhang, J., Manevich, Y., Townsend, D. M., & Tew, K. D. (2013). Causes and consequences of cysteine S-glutathionylation. Journal of Biological Chemistry, 288(37), 26497–26504.
Sources: en.wikipedia.org
== Choanoflagellates == All animals are posited to have evolved from a flagellated eukaryote. Their closest known living relatives are the choanoflagellates, collared flagellates whose cell morphology is similar to the choanocyte cells of certain sponges. Molecular studies place animals in a supergroup called the opisthokonts, which also includes the choanoflagellates, fungi, and a few small parasitic protists. The name comes from the posterior location of the flagellum in motile cells, such as most animal spermatozoa, whereas other eukaryotes tend to have anterior flagella instead.
In adults and children with bipolar disorder, SSRIs may cause a bipolar switch from depression into hypomania/mania, mixed states, or rapid cycling. When taken with mood stabilizers, the risk of switching is not increased; however, when taking SSRIs as a monotherapy, the risk of switching may be twice or three times that of the average. The changes are not often easy to detect and require monitoring by family and mental health professionals. This switch might happen even with no prior (hypo)manic episodes and might therefore not be foreseen by the psychiatrist. In addition to causing a switch from depression to mania, antidepressants may also cause rapid switches between mood states, known as rapid cycling. Some types of antidepressants are more likely to cause a manic switch or rapid cycling. Serotonin-norepinephrine reuptake inhibitors such as venlafaxine or duloxetine, tetracyclic antidepressants such as mirtazapine, or older tricyclic antidepressants are more likely than SSRIs or bupropion to cause manic switches or rapid cycling. Atypical antipsychotics are approved for bipolar depression. The FDA has approved lurasidone, quetiapine, olanzapine/fluoxetine combination, cariprazine, and lumateperone for bipolar depression.
=== Airlines === Airlines are being affected by the shortage of jet fuel in parts of Asia and Oceania. Many airlines in southeast Asia and Oceania are either adding surcharges to fares or cancelling flights or routes. Australia, which sources most of its jet fuel from China, followed by Singapore and South Korea, has 30 days' worth of jet fuel held in reserve. South Korea makes the refined product and exports it around the region, but it relies mostly on crude arriving via the Gulf, so it is considering limiting its exports. Korean Air is the country's third airline to enter "emergency mode", at this point focusing only on internal cost-reduction measures.
=== Comments on homosexuality === During a performance in Nashville, Tennessee, on June 3, 2011, Morgan made remarks about homosexuals, reportedly stating that if his son were gay, his son better speak to him like a man or he would "pull out a knife and stab him." Morgan apologized, saying that he had "gone too far." In response, head of NBC Entertainment Bob Greenblatt and Morgan's coworker on 30 Rock, Tina Fey, stated they did not condone the comments made by Morgan, and were happy to see him make a sincere apology.
Sources: en.wikipedia.org
=== Inflammation === FFAR2 is expressed in various cells involved in the development of inflammatory responses such as neutrophils, monocytes, macrophages, dendritic cells, regulatory T cells, and T helper cells. FFAR2 often appears to be involved in suppressing these cells' pro-inflammatory actions and thereby the development of inflammation. For example: 1) compared to control mice, Ffar2 gene knockout mice developed more severe and unresolving inflammation in colitis, arthritis, peritonitis, and asthma models of inflammation; 2) germ-free mice, which lack intestinal SCFAs, likewise had severer disease in these colitis, arthritis, and asthma models; 3) in a dextran sulphate sodium-induced model of colitis, Ffar2 gene knockout mice developed more severe disease than control mice; 4) two studies found that normal mice but not Ffar2 gene knockout mice fed a prebiotic diet that produces higher intestinal levels of SCFAs were protected from developing allergic responses to food; 5) the latter study also showed that the prebiotic diet was fully protective in Ffar3 gene knockout mice (allergic responses are a subtype of the inflammatory reactions); and 6) studies in mice and humans suggest that FFAR2 is involved in suppressing the pancreatic islet inflammation underlying the development of type 1 diabetes (see previous section). Other studies, however, have reported that FFAR2 promotes inflammation. Two studies found that FFAR2 gene knockdown mice had less severe disease in a dextran sulphate sodium-induce colitis model compared to control mice.
does not necessarily reflect the intermolecular forces between the molecules, it is the energy cost associated with disrupting the pattern and may be thought of as a region where optimum arrangement does not occur and the reduction of enthalpy associated with ideal self-assembly did not occur. An example of this can be seen in a system of hexagonally packed cylinders where defect regions of lamellar structure exist. If
24 November – Colin Renfrew, Baron Renfrew of Kaimsthorn, 87, British archaeologist, academic and peer, member of the House of Lords (1991–2021). 1 December – Sir Richard Carew Pole, 13th Baronet, 85, British aristocrat. 2 December – Rosalie Wilkins, Baroness Wilkins, 78, British politician, member of the House of Lords (1999–2015). (death announced on this date) 8 December – Tony Lloyd, Baron Lloyd of Berwick, 95, British jurist, lord of appeal in ordinary (1993–1998), member of the House of Lords (1993–2015). 15 December – Andrew Bennett, 85, British politician, MP (1974–2005). 18 December – Patrick Conolly-Carew, 7th Baron Carew, 86, Irish equestrian and aristocrat, Member of the House of Lords as a hereditary peer (1994–1999).
These names were later suggested for element 114 (flerovium) and element 116 (moscovium). Flerovium became the name of element 114; the final name proposed for element 116 was instead livermorium, with moscovium later being proposed and accepted for element 115 instead. Traditionally, the names of all noble gases end in "-on", with the exception of helium, which was not known to be a noble gas when discovered. The IUPAC guidelines valid at the moment of the discovery approval however required all new elements be named with the ending "-ium", even if they turned out to be halogens (traditionally ending in "-ine") or noble gases (traditionally ending in "-on"). While the provisional name ununoctium followed this convention, a new IUPAC recommendation published in 2016 recommended using the "-on" ending for new group 18 elements, regardless of whether they turn out to have the chemical properties of a noble gas. The scientists involved in the discovery of element 118, as well as those of 117 and 115, held a conference call on 23 March 2016 to decide their names. Element 118 was the last to be decided upon; after Oganessian was asked to leave the call, the remaining scientists unanimously decided to have the element "oganesson" after him. Oganessian was a pioneer in superheavy element research for sixty years reaching back to the field's foundation: his team and his proposed techniques had led directly to the synthesis of elements 107 through 118.
=== Sequencing === DNA sequencing determines the order of nucleotide bases in a DNA molecule. Synthetic biologists use DNA sequencing in their work in several ways. First, large-scale genome sequencing efforts continue to provide information on naturally occurring organisms. This information provides a rich substrate from which synthetic biologists can construct parts and devices. Second, sequencing can verify that the fabricated system is as intended. Third, fast, cheap, and reliable sequencing can facilitate rapid detection and identification of synthetic systems and organisms.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.